-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$31.00150% Upside
Arcutis Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover Arcutis Biotherapeutics, Inc.?
Arcutis Biotherapeutics, Inc. has been rated by research analysts at Needham, Mizuho Securities, Morgan Stanley, Goldman Sachs in the past 90 days.